The prohibited substance list is continually being revised and updated as new information becomes available on performance enhancing drugs and the 2010 list reflects this. There is a comprehensive list available on the WADA website at:

Some of the main changes in the 2010 list are:
•    The stimulant pseudoephedrine has been reintroduced to the 2010 list. And WADA states, "Given the wide availability of pseudoephedrine-containing medicines, WADA recommends that the reintroduction of pseudoephedrine is supported by active information/education campaign by all stakeholders."
•    Supplemental oxygen is no longer a prohibited method.
•    The International Nonproprietary Name (INN) for the anabolic agent methyltrienolone has been included (metribolone).
•    Growth factors have been addressed in more detail with the addition of examples of growth factors affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilisation, regenerative capacity or fibre type switching.
•    Two beta-2 agonists, salbutamol and salmeterol can be used by inhalation without needing a Therapeutic Use Exemption, TUE, but usage will need to be declared on the doping control form at the time of a test.
•    The maximum dose for the controlled pharmacokinetic study cannot exceed the maximum therapeutic does for inhaled salbutamol.
•    Two hormone antagonists have been added: androstene- 3, 6, 17 trione (6-oxo) and androsta-1,4,6-triene-3,17-dione (androstatrienedione). This is in view of their wide availability as components of nutritional supplements.
•    Glycerol as a masking agent (a plasma expander) is now included.
•    Proteases have been added as a form of manipulation (sample adulteration).
•    The status of intravenous infusions has been reviewed and is prohibited except for those legitimately received "in the course of hospital admissions or clinical investigations."
•    Three stimulants; benfluorex, prenylamine and methylhexaneamine have been added to the closed list of non-specified stimulants.